Cytokine Adsorption in Lung Transplantation: a Randomized Controlled Pilot Study

Status: Recruiting
Location: See location...
Intervention Type: Device
Study Type: Interventional
Study Phase: Not Applicable

Lung transplantation (LTx) remains the gold standard for treating patients with irreversible end-stage pulmonary disease. Of the major organs transplanted, survival in LTx recipients remains the lowest (mean 5 years). Despite improvements, primary graft dysfunction (PGD), as defined by respiratory insufficiency and edema up to 72 hours post LTx, remains the leading cause of early mortality and contributes to the development of chronic lung allograft dysfunction (CLAD) which is the leading cause of late mortality (2). PGD develops within the first 72 hours after LTx. The development of CLAD increases quickly with cumulative incidence of 40-80 % within the first 3-5 years. There is a general lack of efficient treatments for PGD and CLAD. Prevention of PGD is therefore of crucial importance and has a direct impact on survival. The present study is a randomized controlled pilot study which aims to compare patients undergoing LTx with and without the utilization of cytokine adsorption.

Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 70
Healthy Volunteers: No

• Double lung transplantation

• Single organ failure

Other Locations
Skåne University Hospital
Contact Information
Sandra Lindstedt, MD,PhD
Leif Pierre, PhD
Time Frame
Start Date: March 2, 2022
Estimated Completion Date: December 1, 2022
Target number of participants: 10
Active Comparator: Treated
Treatment using the medical cytokine adsorption device in conjunction with lung transplantation
No Intervention: Non-treated
No additional treatment in conjunction with lung transplantation
Related Therapeutic Areas
Leads: Lund University Hospital

This content was sourced from

Similar Clinical Trials